Roche’s drug ocrelizumab was found effective against both relapsing multiple sclerosis and primary progressive multiple sclerosis. Using magnetic resonance imaging, researchers found that ocrelizumab was 95 percent more effective in reducing the inflammatory lesions in the brain than interferon beta-1a.